ISEC Healthcare Ltd · SGX:40T
ISEC Healthcare — Shareholder Meeting (April 2021)
25 slides from ISEC Healthcare's shareholder meeting presentation, Apr 21, 2021
Slide 1: ISEC Healthcare Ltd. 7th Annual General Meeting
ISEC Healthcare Ltd. (“ISEC Healthcare” or the “Company”) 7th Annual General Meeting 21th April 2021 Page 0
Slide 2: Sponsor statement
This announcement has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”) and the Exchange assumes no responsibility for the contents of this docu
Slide 3: Disclaimer
Disclaimer This presentation contains certain financial information and results of operation, and may also contain certain projections, plans, strategies and objectives of the Company which are not statements of historical fact but may constitute “forward-looking statements” that reflect the Company
Slide 4: Table of Content
Table of Content Business Overview Financial Highlights Corporate Developments Outlook Page 3
Slide 5: Business Overview
Business Overview Page 4
Slide 6: Our Presence
Business Overview Our Presence Number of Eye Care Centres Penang (as at 21st April 2021): Sibu Kuala Lumpur Malaysia – 5 Singapore – 1 * Malacca Myanmar – 1 * Asia Pacific Eye Centre in Gleneagles Hospital. An eye- Yew Tee * screening clinic within one of our Johor GP clinic premises in Yew Tee was
Slide 7: Our Competitive Strengths
Business Overview Our Competitive Strengths 1 Highly qualified and experienced specialist doctors 6 Business model aligns the 2 interests of our High quality and specialist doctors with comprehensive range of our Group and eye care services Shareholders 5 Ability to replicate our 3 Well positioned t
Slide 8: Financial Highlights
Financial Highlights Page 7
Slide 9: Consolidated Statement of Comprehensive Income
Financial Highlights Consolidated Statement of Comprehensive Income S$’000 2020 2019 % Change Revenue 36,327 42,872 -15% Cost of sales (20,270) (22,823) -11% Gross profit (“GP”) / GP margin (%) 16,057 / 44.2% 20,049 / 46.8% -20% Other income 1,325 702 89% Selling and distribution expenses (41) (60)
Slide 10: Revenue Breakdown – By Business Segment
Financial Highlights Revenue Breakdown – By Business Segment Include Indah Specialist Exclude Indah Specialist S$’Million S$’Million 36.3 33.2 2020 3.5 2020 3.5 Down Down 32.8 29.7 S$6.6mil S$9.7mil (15%) (23%) 42.9 42.9 2019 4.1 2019 4.1 38.8 38.8 - 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 - 5.0
Slide 11: Revenue Breakdown – By Geographical Segment
Financial Highlights Revenue Breakdown – By Geographical Segment Include Indah Specialist Exclude Indah Specialist S$’Million S$’Million 36.3 33.2 0.4 0.4 2020 2020 28.6 Down 25.5 Down S$6.6mil S$9.7mil 7.3 7.3 (15%) (23%) 42.9 42.9 0.2 0.2 2019 2019 33.2 33.2 9.5 9.5 - 5.0 10.0 15.0 20.0 25.0 30.0
Slide 12: Revenue – 5 Years (2016 – 2020)
Financial Highlights Revenue – 5 Years (2016 – 2020) S$’Million S$2.5 mil (6%) S$3.4 mil (9%) S$6.6 mil (15%) 42.9 S$6.2 mil (20%) 40.4 45.0 37.0 36.3 40.0 30.8 35.0 30.0 25.0 20.0 15.0 10.0 5.0 - 2016 2017 2018 2019 2020 The Group revenue had been increasing between 6% and 20% year-on-year from FY2
Slide 13: Profit attributable to owners – 5 Years (2016 – 2020)
Financial Highlights Profit attributable to owners of Company – 5 Years (2016 – 2020) S$’Million 8.4 7.9 7.5 9.0 8.0 6.4 7.0 4.7 6.0 5.0 4.0 3.0 2.0 1.0 - 2016 2017 2018 2019 2020 In both FY2020 and FY2019, the Group recognised impairment loss for goodwill arising from operations in general health s
Slide 14: Dividends
Financial Highlights Dividends S$’Million 16.0 180.0% 14.0 160.0% 140.0% 12.0 120.0% 10.0 100.0% 8.0 80.0% 6.0 60.0% 4.0 40.0% 2.0 20.0% - 0.0% 2016 2017 2018 2019 2020 Dividends Paid/Payable 4.9 6.2 13.4 4.3 4.4 % of Profit Attributable to owners of Company 76.6% 78.5% 159.5% 57.3% 93.6% Dividends
Slide 15: Corporate Developments
Corporate Developments Page 14
Slide 16: Acquisition of Indah Specialist Eye Centre
Corporate Developments 2020 1) 27 February 2020 – Completion of Acquisition of the Entire Issued and Paid-up Share Capital of Indah Specialist Eye Centre Sdn. Bhd. (“Indah Specialist”) Summary of the acquisition • Aggregate consideration of RM37,360,000 (“Consideration”), approximately a multiple of
Slide 17: Acquisition of Indah Specialist (Cont'd)
Corporate Developments 2020 1) 27 February 2020 – Completion of Acquisition of the Entire Issued and Paid-up Share Capital of Indah Specialist (Cont’d) Summary of the acquisition (Cont’d) • Each of the Vendors has undertaken to the Purchaser not to, during the 5-year period commencing from the date
Slide 18: Joint Venture Company – ISEC (Kuching) Sdn. Bhd.
Corporate Developments 2020 2) 15 July 2020 – Incorporation of a Joint Venture Company – ISEC (Kuching) Sdn. Bhd. • ISEC Sdn. Bhd. (“ISEC KL”), a wholly owned subsidiary of the Company, has entered into a joint venture agreement (the “JV Agreement”) with Dr Chua Chung Nen (“Dr Chua”) to incorporate
Slide 19: Joint Venture Company (Cont'd)
Corporate Developments 2020 2) 15 July 2020 – Incorporation of a Joint Venture Company – ISEC (Kuching) Sdn. Bhd. (Cont’d) • The investment in the JVC will be funded by internal resources. Following the Company’s investment in the JVC, the JVC became an indirect subsidiary of the Company. Page 18
Slide 20: Bank loan for land and building purchase
Corporate Developments 2020 3) 6 August 2020 – Entering into bank loan by ISEC (Penang) Sdn. Bhd. (“ISEC Penang”), for the purpose of purchase of land and building • ISEC Penang, a wholly-owned indirect subsidiary of the Company, entered into a 5-year term loan facility to partially finance the acqu
Slide 21: Launch of new eye-screening clinic in Singapore
Corporate Developments 2021 1) Early 2021 – Launch of new eye-screening clinic in Singapore’s neighbourhood hub • To further expand its reach in Singapore’s neighbourhood hub, in early 2021, the Group had set up an eye-screening clinic within the premises of one of its general practice clinics in Ye
Slide 22: Outlook
Outlook Page 21
Slide 23: Outlook: Coronavirus 2019 Outbreak
Outlook Coronavirus 2019 (“COVID-19”) Outbreak • The Group expects the operating environment in the current year ending 31 December 2021 to be challenging. While we are optimistic that our performance will improve along with the expected but careful resumption of travel, business and lifestyle activ
Slide 24: Outlook: Political Situation in Myanmar
Outlook Political Situation in Myanmar • The Group is closely monitoring our clinical operations in Myanmar, where the country had declared a state of emergency for a year since 1 February 2021. The political situation remains uncertain and the Group is currently unable to reasonably ascertain the f
Slide 25: Thank You
Thank You Page 24